Tata 1mg nears Rs 3,000 crore revenue in FY26 as diagnostics-led strategy turns profitable
Five years after Tata Digital acquired a majority stake, Tata 1mg has grown revenue roughly 10X from Rs 309 crore while pursuing disciplined discounting, diagnostics and clinics rather than rapid delivery. Its diagnostics business has crossed Rs 600 crore in annualised revenue.
What happened
Tata 1mg reported nearly Rs 3,000 crore FY26 revenue and net profitability after prioritising diagnostics, clinics and disciplined discounting over quick
Key facts
- Tata Digital acquired a 55% majority stake in 1mg in 2021
- Revenue was Rs 309 crore at acquisition
- Revenue reached nearly Rs 3,000 crore in FY26
- Revenue grew 10X over five years
- Diagnostics annualised revenue exceeded Rs 600 crore
- PharmEasy's 2024 equity valuation was about $710 million versus a $5.6 billion peak in 2021
Why this matters
Tata 1mg’s diagnostics-led expansion highlights the strategic value of acquiring or partnering for higher-margin healthcare services that deepen pharmacy customer retention.
What to watch
- Whether diagnostics annualised revenue sustains growth above the Rs 600 crore base and expands as a share of total revenue.
- Evidence that net profitability persists after marketing, expansion and technology investment rather than being a one-period outcome.
- Changes in discounting, delivery fees and customer-acquisition spending by PharmEasy, Netmeds, Apollo 24/7 and quick-commerce platforms.
- Growth in repeat customers, chronic-therapy subscriptions and medicine-plus-diagnostics order attachment.
- Regulatory developments on e-pharmacy operations, prescription validation, data privacy and diagnostic sample collection.
- New Tata Digital, Tata Neu, insurer or hospital-network integrations that lower acquisition costs or deepen ecosystem retention.
- Expand diagnostics-led chronic-care packages combining tests, doctor consultations and recurring medicine refills.
- Increase home sample-collection density and regional laboratory partnerships in high-frequency urban markets.
- Use profitability to selectively acquire customers through Tata ecosystem cross-selling rather than broad discount campaigns.
- Develop employer, insurer and corporate-health partnerships to shift diagnostics demand toward recurring contracted revenue.
- Invest in private-label wellness and medical-consumables categories where repeat purchase and gross margins can exceed prescription-medicine economics.